Ferumoxytol

Iron Deficiency Anemia, Chronic Kidney Disease
Treatment
4 FDA approvals
20 Active Studies for Ferumoxytol

What is Ferumoxytol

FerumoxytolThe Generic name of this drug
Treatment SummaryFerumoxytol is a medication used to treat iron deficiency anemia in adults with chronic kidney disease. It is given through an intravenous injection and is a solution of iron oxide nanoparticles coated in a semi-synthetic carbohydrate shell. The injection is given at a high dose and quickly goes into the bloodstream.
Feridexis the brand name
image of different drug pills on a surface
Ferumoxytol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Feridex
Ferumoxytol
2008
3

Approved as Treatment by the FDA

Ferumoxytol, otherwise known as Feridex, is approved by the FDA for 4 uses including Chronic Kidney Disease and Chronic Kidney Disease (CKD) .
Chronic Kidney Disease
Chronic Kidney Disease (CKD)
Iron Deficiency Anemia (IDA)
Iron Deficiency Anemia

Effectiveness

How Ferumoxytol Affects PatientsFerumoxytol is a drug used to measure hemoglobin, serum ferritin, and transferrin saturation levels. It has been shown to be more effective than oral iron in clinical studies. It can also be used as a contrast agent for MRI scans, as it stays in the bloodstream and allows for data collection over a longer period of time. Iron is important for many bodily functions, including oxidation-reduction reactions and enzymes in the mitochondria. Low iron levels can lead to anemia, decreased oxygen delivery, and learning or thermoregulation defects.
How Ferumoxytol works in the bodyFeraheme is a drug made of iron covered by a carbohydrate shell. When this drug enters the body, the shell breaks apart and releases iron. This iron is then stored in the body or used to make hemoglobin. Iron is important for many processes in the body including allowing cells to use oxygen and regulating the body's temperature. Feraheme replaces iron stores more effectively than oral iron supplements and can also be used to make MRI images of the body by darkening contrast media-containing structures.

When to interrupt dosage

The measure of Ferumoxytol is contingent upon the diagnosed condition. The amount likewise fluctuates as per the technique of delivery (e.g. Injection - Intravenous or Solution) noted in the table underneath.
Condition
Dosage
Administration
Chronic Kidney Disease
, 30.0 mg/mL, 0.051 mg/mL, 51.0 mg/mL, 11.2 mg/mL
, Intravenous, Solution, Solution - Intravenous, Injection, Injection - Intravenous
Iron Deficiency Anemia
, 30.0 mg/mL, 0.051 mg/mL, 51.0 mg/mL, 11.2 mg/mL
, Intravenous, Solution, Solution - Intravenous, Injection, Injection - Intravenous

Warnings

There are 20 known major drug interactions with Ferumoxytol.
Common Ferumoxytol Drug Interactions
Drug Name
Risk Level
Description
Technetium Tc-99m oxidronate
Major
Ferumoxytol can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.
3-Aza-2,3-Dihydrogeranyl Diphosphate
Minor
Ferumoxytol can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Phosphate
Minor
Ferumoxytol can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium phosphate dihydrate
Minor
Ferumoxytol can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dipotassium phosphate
Minor
Ferumoxytol can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferumoxytol Toxicity & Overdose RiskFeraheme may cause serious allergic reactions, including anaphylaxis, which were reported in 0.2% of people who used it. Other allergic reactions such as itching, rash, hives, or wheezing were reported in 3.7% of people who used it. It has not been tested to determine if it can cause cancer, and studies have not found it to cause fertility issues in animals. Feraheme may also cause low blood pressure, iron overload, and alterations to MRI imaging, which could last up to 12 weeks after the last dose.
image of a doctor in a lab doing drug, clinical research

Ferumoxytol Novel Uses: Which Conditions Have a Clinical Trial Featuring Ferumoxytol?

118 active studies are currently being conducted to evaluate the effectiveness of Ferumoxytol for the amelioration of Iron deficiency anemia.
Condition
Clinical Trials
Trial Phases
Iron Deficiency Anemia
7 Actively Recruiting
Phase 3, Phase 4, Phase 2, Not Applicable
Chronic Kidney Disease
102 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1

Patient Q&A Section about ferumoxytol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Feraheme?

"Dizziness, fainting, low blood pressure, injection site reactions, nausea, vomiting, stomach pain, and diarrhea are all possible side effects of this medication."

Answered by AI

What is the brand name for ferumoxytol?

"Feraheme is a drug used to treat iron deficiency anemia. It is given as an injection and works by replacing the iron in the body."

Answered by AI

What is ferumoxytol made of?

"Ferumoxytol is an intravenous iron preparation that is used to treat the anemia of chronic kidney disease (CKD). It is a carbohydrate-coated, superparamagnetic iron oxide nanoparticle. Because there is very little free iron in the preparation, doses of 510 mg have been safely administered in as little as 17 seconds."

Answered by AI

What is ferumoxytol injection for?

"Ferumoxytol is an iron replacement product that is injected to treat iron deficiency anemia in patients with chronic kidney disease or who have not had success with taking oral iron supplements in the past."

Answered by AI

Clinical Trials for Ferumoxytol

Image of Trinity Research Group in Dothan, United States.

Velocity pAVF System for Kidney Failure

18 - 80
All Sexes
Dothan, AL
This study will evaluate the Velocity Percutaneous Arteriovenous Fistula (pAVF) System, a new minimally invasive method for creating dialysis access. People with kidney failure often require dialysis, which depends on having a reliable arteriovenous fistula (AVF). Traditionally, AVFs are created with surgery, but surgery can involve incisions, longer recovery, and sometimes additional procedures before the AVF can be used. The Velocity System is designed to create an AVF through a small puncture in the skin using a catheter-based approach, without open surgery. This pivotal study will assess how safe the procedure is and how well it works for patients who need dialysis. The study will take place at multiple centers in the United States and will enroll adults with kidney failure who are candidates for fistula creation. Participants will undergo the Velocity procedure and then be followed closely with exams, ultrasounds, and dialysis assessments for up to five years. Taking part is voluntary. Patients may benefit from a less invasive approach to dialysis access, but the main goal is to collect information that could improve future care for people with kidney failure.
Recruiting
Has No Placebo
Trinity Research Group (+4 Sites)Venova Medical
Image of University of Alabama at Birmingham in Birmingham, United States.

Empagliflozin for Chronic Kidney Disease

2 - 17
All Sexes
Birmingham, AL
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD. Other goals of the study are to find out how empagliflozin is tolerated and handled by the body in children and adolescents with CKD. Participants are put into 2 groups randomly, which means by chance. One group takes empagliflozin and the other group takes placebo. Placebo looks like empagliflozin but does not contain any medicine. Participants are twice as likely to be in the empagliflozin group. Participants take empagliflozin or placebo as tablets once a day for 6 months. After 6 months, participants in both groups take empagliflozin as tablets once a day for 1 year. Participants are in the study for a little over a year and a half. During this time, they visit the study site about 15 times and get at least 5 phone or video calls from the site staff. At the visits, the doctors take blood and urine samples from the participants. The doctors also regularly check participants' health and take note of any unwanted effects.
Phase 3
Waitlist Available
University of Alabama at Birmingham (+33 Sites)Boehringer Ingelheim
Image of Centre hospitalier affilié universitaire régional de Trois-Rivières in Trois-Rivières, Canada.

Endoscopic Evaluation for Iron-Deficiency Anemia

18 - 90
All Sexes
Trois-Rivières, Canada
This is a single-center, randomized pilot study evaluating the feasibility and safety of two management strategies for patients on antithrombotic therapy who present with obscure gastrointestinal bleeding (OGIB). Participants will be randomized to either repeated endoscopic evaluations or a conservative medical approach with limited testing. The study aims to assess whether conservative management yields similar clinical outcomes and quality of life compared to standard repeated endoscopic procedures. Results will inform the design of a larger trial and address the current lack of guidelines for managing recurrent iron-deficiency anemia in this patient population.
Recruiting
Has No Placebo
Centre hospitalier affilié universitaire régional de Trois-RivièresÉva Mathieu, PhD
Have you considered Ferumoxytol clinical trials? We made a collection of clinical trials featuring Ferumoxytol, we think they might fit your search criteria.Go to Trials
Have you considered Ferumoxytol clinical trials? We made a collection of clinical trials featuring Ferumoxytol, we think they might fit your search criteria.Go to Trials
Image of Foothills Medical Centre in Calgary, Canada.

Decision Aid for Chronic Kidney Disease and Coronary Artery Disease

18+
All Sexes
Calgary, Canada
Many people with kidney disease also have heart disease. The procedures used to diagnose and treat heart disease (e.g., angiograms, angioplasty, or surgery) can improve symptoms and cardiovascular outcomes, but pose greater risks of kidney complications for people with chronic kidney disease. It's therefore important that patients with kidney disease and their health care providers understand the benefits versus risks of these procedures and use that information to make informed decisions regarding their health care. Prior research done with patients with kidney disease and their health care providers has led to the develop of a decision aid designed to help doctors provide personalized information on the benefits versus risks of having a heart procedure, as well as help patients communicate their own values and preferences to their doctor. This information is crucial for shared decision making, as previous research has shown that preferences and values vary for individual patients with kidney diseases, and should be incorporated into the decision-making process for heart disease management. The decision aid, called "My Heart Care and CKD", supports shared decision-making between patients with kidney disease and heart their care providers. This trial will implement and evaluate this decision aid within cardiovascular care in a pilot trial in Canada.
Waitlist Available
Has No Placebo
Foothills Medical Centre (+1 Sites)Matthew T James, MD
Have you considered Ferumoxytol clinical trials? We made a collection of clinical trials featuring Ferumoxytol, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security